← Back to Calendar
Indication
Genitourinary Oncology — San Francisco, CA
Key Notes
ASCO GU 2026: February 26–28, San Francisco. Key GU oncology data. CAPItello-281 capivasertib+abiraterone prostate cancer Phase 3 data presented here (ahead of ODAC April 30, 2026). Updates on PSMA-targeted therapies, checkpoint inhibitors in bladder cancer, and novel prostate cancer combinations.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.